TapImmune, Inc. (TPIV) - Description of business
TapImmune Inc. engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine, which is under preclinical trial used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company was founded in 1999 and is based in Seattle, Washington.